No Data
Changjiang Pharmaceutical Group (300391.SZ): Main business includes traditional chinese medicine decoction pieces, pharmaceutical wholesale, photovoltaic equipment, etc.
Changjiang Pharmaceutical Group (300391.SZ) stated on the investor interactive platform on November 12th that the company's main business currently includes traditional chinese medicine decoction pieces, pharmaceutical wholesale, photovoltaic equipment, etc. In addition, its subsidiary Ningxia Chang Pharmaceutical Nutrition has launched a variety of tea drinks and medicinal food homologous products, including 15 kinds of liver-replenishing tea with authentic goji and astragalus as formulas, 20 kinds of moisture-expelling tea, 9 kinds of eight-treasure tea, as well as compressed confectioners and other medicinal food homologous varieties.
Changyao Holdings: Report for the third quarter of 2024
changjiang pharmaceutical group (300391.SZ): net loss of 0.181 billion yuan in the first three quarters.
Changjiang Pharmaceutical Group (300391.SZ) announced its third-quarter report for 2024 on October 29th, with the company achieving revenue of 0.101 billion yuan for the first three quarters, a year-on-year decrease of 90.12%; net income attributable to shareholders of the listed company was -0.181 billion yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.179 billion yuan; basic earnings per share was -0.5166 yuan.
Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Shares Climb 37% But Its Business Is Yet to Catch Up
Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 28%
Changyao Holdings: 2024 Semi-Annual Report Summary
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Surges 52% Yet Its Low P/S Is No Reason For Excitement
